Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.
作者信息
Bharucha Adil E, Waldman Scott A
出版信息
Gastroenterology. 2010 Mar;138(3):813-7. doi: 10.1053/j.gastro.2010.01.022. Epub 2010 Jan 27.
Abstract
摘要
相似文献
1
Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.从微生物性腹泻发病机制中汲取经验用于慢性便秘的管理。
Gastroenterology. 2010 Mar;138(3):813-7. doi: 10.1053/j.gastro.2010.01.022. Epub 2010 Jan 27.
2
Efficacy of linaclotide for patients with chronic constipation.利那洛肽治疗慢性便秘患者的疗效。
Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.
3
Lubiprostone (Amitiza) for opioid-induced constipation.鲁比前列酮（Amitiza）用于治疗阿片类药物引起的便秘。
Med Lett Drugs Ther. 2013 Jun 10;55(1418):47-8.
4
Plecanatide (Trulance) for chronic idiopathic constipation.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):66-68.
5
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.确定新型回肠胆汁酸转运蛋白抑制剂埃洛比昔巴特在慢性便秘日本患者中的最佳临床剂量：一项 II 期、多中心、双盲、安慰剂对照随机临床试验。
J Gastroenterol. 2018 Apr;53(4):525-534. doi: 10.1007/s00535-017-1383-5. Epub 2017 Aug 24.
6
How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?对于便秘型肠易激综合征患者，我们如何缓解其肠道和腹部症状？
Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5 Suppl 1):21-6. doi: 10.1586/17474124.2013.820046.
7
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.利那洛肽在便秘型肠易激综合征患者的 IIb 期研究中改善了腹痛和排便习惯。
Gastroenterology. 2010 Dec;139(6):1877-1886.e2. doi: 10.1053/j.gastro.2010.08.041. Epub 2010 Aug 27.
8
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.一项 3309（一种胆汁酸转运蛋白抑制剂）治疗慢性特发性便秘的随机安慰剂对照 2b 期临床试验。
Am J Gastroenterol. 2011 Oct;106(10):1803-12. doi: 10.1038/ajg.2011.162. Epub 2011 May 24.
9
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.利那洛肽治疗中重度腹胀的慢性特发性便秘患者：一项随机对照试验
PLoS One. 2015 Jul 29;10(7):e0134349. doi: 10.1371/journal.pone.0134349. eCollection 2015.
10
Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study.结晶乳果糖制剂（SK-1202）在日本慢性便秘患者中的疗效和安全性：一项随机、双盲、安慰剂对照、剂量探索研究。
J Gastroenterol. 2019 Jun;54(6):530-540. doi: 10.1007/s00535-018-01545-7. Epub 2019 Jan 14.
引用本文的文献
1
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.一项探索健康志愿者中多卡纳肽（SP-333）27 毫克结直肠生物活性的 I 期双盲、安慰剂对照试验。
Cancer Biol Ther. 2021 Dec 2;22(10-12):544-553. doi: 10.1080/15384047.2021.1967036. Epub 2021 Oct 10.
2
Chronic Constipation.慢性便秘。
Mayo Clin Proc. 2019 Nov;94(11):2340-2357. doi: 10.1016/j.mayocp.2019.01.031. Epub 2019 May 1.
3
Existing and emerging therapies for managing constipation and diarrhea.用于治疗便秘和腹泻的现有和新兴疗法。
Curr Opin Pharmacol. 2017 Dec;37:158-166. doi: 10.1016/j.coph.2017.10.015. Epub 2017 Nov 21.
4
Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.口服利那洛肽在人结肠中用于癌症化学预防的生物活性。
Cancer Prev Res (Phila). 2017 Jun;10(6):345-354. doi: 10.1158/1940-6207.CAPR-16-0286. Epub 2017 Apr 10.
5
Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.治疗性靶向鸟苷酸环化酶-C：尿鸟苷素类似物plecanatide的计算模型
Pharmacol Res Perspect. 2017 Mar 12;5(2):e00295. doi: 10.1002/prp2.295. eCollection 2017 Apr.
6
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition.《2015年修订版韩国慢性功能性便秘诊断和治疗指南》
J Neurogastroenterol Motil. 2016 Jul 30;22(3):383-411. doi: 10.5056/jnm15185.
7
Optimal management of constipation associated with irritable bowel syndrome.肠易激综合征相关性便秘的优化管理
Ther Clin Risk Manag. 2015 May 30;11:691-703. doi: 10.2147/TCRM.S54298. eCollection 2015.
8
Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.针对以便秘为主的肠易激综合征和慢性便秘的新兴药物疗法。
J Neurogastroenterol Motil. 2014 Apr 30;20(2):141-51. doi: 10.5056/jnm.2014.20.2.141.
9
Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Clin Med Insights Gastroenterol. 2013 Jul 31;6:21-32. doi: 10.4137/CGast.S10550. eCollection 2013.
10
Review article: Linaclotide for the management of irritable bowel syndrome with constipation.综述文章：利那洛肽治疗便秘型肠易激综合征。
Aliment Pharmacol Ther. 2014 Feb;39(4):371-84. doi: 10.1111/apt.12604. Epub 2014 Jan 16.
本文引用的文献
1
Efficacy of linaclotide for patients with chronic constipation.利那洛肽治疗慢性便秘患者的疗效。
Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.
2
Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study.普芦卡必利治疗老年便秘患者的安全性评估：一项双盲、安慰剂对照研究。
Neurogastroenterol Motil. 2009 Dec;21(12):1256-e117. doi: 10.1111/j.1365-2982.2009.01398.x. Epub 2009 Sep 9.
3
Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial.基层医疗中，可溶或不可溶纤维用于肠易激综合征？随机安慰剂对照试验。
BMJ. 2009 Aug 27;339:b3154. doi: 10.1136/bmj.b3154.
4
Phenotypic variation of colonic motor functions in chronic constipation.慢性便秘患者结肠运动功能的表型变化。
Gastroenterology. 2010 Jan;138(1):89-97. doi: 10.1053/j.gastro.2009.07.057. Epub 2009 Aug 4.
5
Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.美国食品药品监督管理局为肠易激综合征和功能性消化不良的新药研发开了绿灯。
Am J Gastroenterol. 2009 Jun;104(6):1339-41. doi: 10.1038/ajg.2009.295.
6
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.临床试验：普芦卡必利治疗严重慢性便秘的疗效、对生活质量的影响以及安全性和耐受性——一项为期12周的随机双盲安慰剂对照研究。
Aliment Pharmacol Ther. 2009 Feb 1;29(3):315-28. doi: 10.1111/j.1365-2036.2008.03884.x. Epub 2008 Nov 8.
7
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.普芦卡必利（Resolor）用于治疗对泻药不满意的重度慢性便秘患者。
Gut. 2009 Mar;58(3):357-65. doi: 10.1136/gut.2008.162404. Epub 2008 Nov 5.
8
Subcellular alterations that lead to diarrhea during bacterial pathogenesis.细菌致病过程中导致腹泻的亚细胞改变。
Trends Microbiol. 2008 Nov;16(11):535-42. doi: 10.1016/j.tim.2008.08.004. Epub 2008 Sep 25.
9
Therapeutic targeting: a crucible for individualized medicine.治疗靶点：个体化医疗的关键要素。
Clin Pharmacol Ther. 2008 May;83(5):651-4. doi: 10.1038/clpt.2008.65.
10
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.多中心、为期4周的双盲随机安慰剂对照试验，研究局部作用的2型氯离子通道激活剂鲁比前列酮治疗慢性便秘患者的疗效。
Am J Gastroenterol. 2008 Jan;103(1):170-7. doi: 10.1111/j.1572-0241.2007.01524.x. Epub 2007 Oct 4.
Zotero 插件